Awareness of the risk of developing medication-related osteonecrosis of the jaw among bisphosphonate users

J Int Med Res. 2020 Sep;48(9):300060520955066. doi: 10.1177/0300060520955066.

Abstract

Objective: In this retrospective observational study, we evaluated awareness among patients using bisphosphonates (BPs) regarding the risk of developing medication-related osteonecrosis of the jaw (MRONJ) and whether they received appropriate dental screening and treatment prior to commencing medication.

Methods: Patients using BPs who attended the endodontics clinic at Jordan University Hospital in 2019 were interviewed using a pre-designed questionnaire. Data were analysed using descriptive statistics and chi-squared tests.

Results: In total, 110 patients were interviewed (84 women, 26 men; age 40-78 years). A total of 94 patients were using oral BP and 16 received intravenous (IV) BP. We found that only 12.4% of participants were aware about the risk of MRONJ following BP use, and only one third of them has received information from their prescribing physicians. In total, 5% of participants were referred to a dentist for screening prior to initiating BP treatment. Patients receiving IV BP and those with a university-level education had better awareness about the risk of MRONJ than oral BP users and those with a high school education level.

Conclusion: Patients' awareness about MRONJ risk was low in our population. Better patient education and collaboration among physicians and dentists are needed prior to starting BP treatment.

Keywords: Medication-related osteonecrosis of the jaw; antiresorptive drugs; bisphosphonates; multidisciplinary team; patient education; risk awareness.

Publication types

  • Observational Study

MeSH terms

  • Adult
  • Aged
  • Bisphosphonate-Associated Osteonecrosis of the Jaw* / diagnosis
  • Bisphosphonate-Associated Osteonecrosis of the Jaw* / epidemiology
  • Bisphosphonate-Associated Osteonecrosis of the Jaw* / etiology
  • Bone Density Conservation Agents*
  • Diphosphonates / adverse effects
  • Female
  • Humans
  • Jordan
  • Male
  • Middle Aged
  • Retrospective Studies

Substances

  • Bone Density Conservation Agents
  • Diphosphonates